Literature DB >> 17438573

Prospects for the use of NK cells in immunotherapy of human cancer.

Hans-Gustaf Ljunggren1, Karl-Johan Malmberg.   

Abstract

Current insights into the molecular specificities that regulate natural killer (NK)-cell function suggest that it might be possible to design NK-cell-based immunotherapeutic strategies against human cancer. Here, we describe evidence for NK-cell targeting of human tumours and address crucial questions that, in our opinion, require consideration for the development of successful NK-cell-based therapies. Appropriately used, we predict that NK cells will have a role, both directly and in combination with other treatment modalities, in future treatment of cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17438573     DOI: 10.1038/nri2073

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  216 in total

1.  γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Authors:  Mounia Sabrina Braza; Bernard Klein; Geneviève Fiol; Jean-François Rossi
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

2.  Effective modulation of CD4(+)CD25 (+high) regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2.

Authors:  Guangxian Liu; Wuwei Yang; Mei Guo; Xiaoqing Liu; Naixiang Huang; Dingfeng Li; Zefei Jiang; Wenfeng Yang; Weijing Zhang; Hang Su; Zhiqing Liu; Tieqiang Liu; Dongmei Wang; Shan Huang; Bo Yao; Qiuhong Man; Lijuan Qiu; Xuedong Sun; Yuying Sun; Bing Liu
Journal:  Cancer Immunol Immunother       Date:  2012-06-22       Impact factor: 6.968

3.  A novel bispecific antibody, BiSS, with potent anti-cancer activities.

Authors:  Bin Dong; Changhua Zhou; Ping He; Jing Li; Siqi Chen; Ji Miao; Qing Li; Zhong Wang
Journal:  Cancer Biol Ther       Date:  2016-02-01       Impact factor: 4.742

4.  An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.

Authors:  S P Koerner; M C André; J S Leibold; P C Kousis; A Kübler; M Pal; S P Haen; H-J Bühring; L Grosse-Hovest; G Jung; H R Salih
Journal:  Leukemia       Date:  2016-07-20       Impact factor: 11.528

5.  Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.

Authors:  Melissa A Geller; David A Knorr; David A Hermanson; Lee Pribyl; Laura Bendzick; Valarie McCullar; Jeffrey S Miller; Dan S Kaufman
Journal:  Cytotherapy       Date:  2013-10       Impact factor: 5.414

6.  hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.

Authors:  Wen Jiang; Cai Zhang; Zhigang Tian; Jian Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-08       Impact factor: 4.553

7.  IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.

Authors:  Margherita Boieri; Aina Ulvmoen; Amanda Sudworth; Clare Lendrem; Matthew Collin; Anne M Dickinson; Lise Kveberg; Marit Inngjerdingen
Journal:  Oncoimmunology       Date:  2017-01-17       Impact factor: 8.110

Review 8.  Natural killer cells in immunodefense against infective agents.

Authors:  Nicolas Zucchini; Karine Crozat; Thomas Baranek; Scott H Robbins; Marcus Altfeld; Marc Dalod
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

9.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

10.  Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells.

Authors:  Ulrich Langenkamp; Uwe Siegler; Simon Jörger; Stefan Diermayr; Alois Gratwohl; Christian P Kalberer; Aleksandra Wodnar-Filipowicz
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.